JB 991

Drug Profile

JB 991

Alternative Names: JB991

Latest Information Update: 23 Feb 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synphora
  • Developer Swedish Orphan Biovitrum; Synphora
  • Class Anti-inflammatories; Prostaglandins; Skin disorder therapies
  • Mechanism of Action Apoptosis stimulants; Prostaglandin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Glaucoma; Psoriasis

Most Recent Events

  • 23 Feb 2010 No development reported - Phase-II for Psoriasis in Sweden (Topical)
  • 23 Feb 2010 No development reported - Preclinical for Glaucoma in Sweden (Topical)
  • 14 Jan 2010 Biovitrum has merged with Swedish Orphan to form Swedish Orphan Biovitrum
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top